Trial Profile

A phase 1 trial evaluating HWK-206 in small cell lung cancer and neuroendocrine neoplasms

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 23 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HWK-206 (Primary)
Indications Neuroendocrine tumours; Small cell lung cancer
Focus Adverse reactions

Most Recent Events

12 Mar 2026 According to Aadi Bioscience media release, the company plans to start the trial in Q3 2026.
07 Aug 2025 According to Whitehawk Therapeutics media release, the company is on track to file the IND for HWK-206 by mid-2026.
06 Apr 2025 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com